COMMUNIQUÉS West-GlobeNewswire

Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
20/02/2024
–   ARV-102 is a novel oral PROTAC® protein degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2 (LRRK2) – – The Phase 1 trial of ARV-102 will evaluate safety, tolerability, [...]
Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results
20/02/2024
WALTHAM, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2023 [...]
Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
20/02/2024
PITTSBURGH, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, will report its fourth quarter and full year 2023 financial results on Monday [...]
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research
20/02/2024
- Additional new data demonstrate VY-TAU01, Voyager’s lead antibody targeting pathological tau, was well-tolerated and demonstrated favorable pharmacokinetics in non-human primates (NHPs) - - Data to be presented at the [...]
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
20/02/2024
SAN FRANCISCO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2023 financial results on Monday, February 26 after the market close. FibroGen will also conduct [...]
SweetWater Brewing Teams Up With Major League Soccer’s Atlanta United FC as Official Craft Beer Partner
20/02/2024
ATLANTA, Feb. 20, 2024 (GLOBE NEWSWIRE) -- SweetWater Brewing Company (“SweetWater Brewing” or “SweetWater”), Atlanta’s premier craft brewer and a subsidiary of Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ: [...]
Acquisition of Freeline by Syncona Becomes Effective
20/02/2024
LONDON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (“Freeline”) and Syncona Ltd (“Syncona”) today announced that, in connection with Syncona’s acquisition of Freeline by way of a [...]
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
20/02/2024
Total 4Q and full year 2023 net product revenue of $71.5 million and $204.9 million, respectively, representing year-over-year growth of 193% and 309% Auvelity 4Q and full year 2023 net product sales of $49.0 million [...]
ANI Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
20/02/2024
BAUDETTE, Minn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, [...]
Teleflex to Present at the 45th Annual Raymond James Institutional Investors Conference
20/02/2024
WAYNE, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 45th Annual Raymond James Institutional Investors Conference at the [...]
Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock
20/02/2024
SAN CARLOS, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (“Iovance” or “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal [...]
Merakris Therapeutics to Release Final Part 1 Data From Phase 2 Multicenter Investigational Drug Study for Dermacyte® Liquid
20/02/2024
Clinical trial data will be presented at annual Treasure Hunt Podiatry and Wound Conference in Los Angeles, CA, February 24-25 RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Merakris Therapeutics [...]
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
20/02/2024
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 fourth quarter and full year financial results and its management will host a [...]
RetinAI Discovery® platform and AI tools launched to improve decision workflows, referrals and patient management in Clinics for Ophthalmologists and Optometrists
20/02/2024
BERN, Switzerland and BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ikerian AG and RetinAI Inc. US (“RetinAI”), a leader in developing software solutions for image processing and artificial intelligence (AI) in [...]
Philips delivers strong ESG performance in 2023
20/02/2024
February 20, 2024 1.88 billion lives improved by Philips’ health technology products and services; on track to improve 2 billion lives by 2025 Through its industry leading innovations and partnerships, Philips helps [...]
Philips publishes its Annual Report 2023
20/02/2024
February 20, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2023. Philips’ Annual Report 2023 will be on the agenda of the [...]
Philips proposes to re-appoint Chairman Feike Sijbesma and Peter Löscher and nominates Benoît Ribadeau-Dumas as member of the Supervisory Board
20/02/2024
February 20, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it proposes to re-appoint Chairman Feike Sijbesma and Peter Löscher as [...]
Roche Diagnostics and BioPorto expand collaboration
20/02/2024
20 February 20, 2024 Announcement no. 02 Roche Diagnostics and BioPorto expand collaboration COPENHAGEN, DENMARK and BOSTON, MA, 20 February, 2024, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR [...]
Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results
20/02/2024
Press Release – No. 2 / 2024 Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results Copenhagen, Denmark, February 20, 2024 – a Zealand Pharma A/S (CVR-no. 20045078 [...]

Pages